Bank Julius Baer & Co. Ltd Zurich Lowers Holdings in CVS Health Co. (NYSE:CVS)

Bank Julius Baer & Co. Ltd Zurich trimmed its holdings in CVS Health Co. (NYSE:CVS) by 27.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,580 shares of the pharmacy operator’s stock after selling 605 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in CVS Health were worth $125,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Atticus Wealth Management LLC lifted its position in shares of CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after buying an additional 219 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in shares of CVS Health by 111.5% in the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after buying an additional 243 shares in the last quarter. ZRC Wealth Management LLC lifted its position in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock worth $39,000 after buying an additional 400 shares in the last quarter. Coston McIsaac & Partners increased its stake in CVS Health by 42.6% during the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock worth $42,000 after acquiring an additional 161 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in CVS Health during the fourth quarter valued at approximately $50,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Down 0.2 %

CVS opened at $67.18 on Monday. The stock’s fifty day moving average is $74.42 and its two-hundred day moving average is $73.67. The company has a market capitalization of $84.68 billion, a P/E ratio of 10.40, a PEG ratio of 0.89 and a beta of 0.52. CVS Health Co. has a 52 week low of $64.41 and a 52 week high of $83.25. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, topping the consensus estimate of $2.01 by $0.11. The company had revenue of $93.81 billion for the quarter, compared to the consensus estimate of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. CVS Health’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the business posted $1.99 EPS. Analysts forecast that CVS Health Co. will post 8.31 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 annualized dividend and a yield of 3.96%. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Leerink Partnrs restated an “outperform” rating on shares of CVS Health in a research report on Monday, February 26th. SVB Leerink assumed coverage on CVS Health in a research report on Monday, February 26th. They set an “outperform” rating and a $88.00 price objective on the stock. Barclays assumed coverage on CVS Health in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective on the stock. StockNews.com downgraded CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $87.00 price objective on shares of CVS Health in a research report on Wednesday, April 10th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.44.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.24% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.